Fundraising Fox
Regatta Bio
1 known investors
Find your way into Regatta Bio
Sign up to see every warm intro you have to Regatta Bio
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Regatta Bio team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Regatta Bio develops precision regulatory T-cell (Treg) therapies aimed at inducing immune tolerance for patients with immune-driven conditions such as chronic graft-versus-host disease, transplant rejection, autoimmune diseases, and inflammatory conditions. The company positions its approach as an alternative to broad immunosuppression across cell transplants, organ transplants, and autoimmunity.
Investors · 1
Frequently asked questions
- What does Regatta Bio do?
- Regatta Bio develops precision regulatory T-cell (Treg) therapies aimed at inducing immune tolerance for patients with immune-driven conditions such as chronic graft-versus-host disease, transplant rejection, autoimmune diseases, and inflammatory conditions. The company positions its approach as an alternative to broad immunosuppression across cell transplants, organ transplants, and autoimmunity.
- Who are Regatta Bio's investors?
- Regatta Bio's investors include Panacea Venture.